End Stage Renal Disease (ESRD) Drug Market 2024 | Market Share, Size, Industry Growth, Competitive Landscape, Share & Forecast To 2033

Overview and Scope
End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person’s kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD).

Sizing and Forecast
The end stage renal disease (esrd) drug market size has grown rapidly in recent years. It will grow from $116.32 billion in 2023 to $132.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.2%.  The  growth in the historic period can be attributed to increasing incidence of end stage renal disease, growing aging population, improved access to healthcare services, government initiatives and policies, increasing adoption of renal replacement therapies.

The end stage renal disease (esrd) drug market size is expected to see rapid growth in the next few years. It will grow to $232.13 billion in 2028 at a compound annual growth rate (CAGR) of 15.0%.  The growth in the forecast period can be attributed to emerging therapies and drug innovations, increasing healthcare expenditure, rising global burden of chronic kidney diseases, personalized medicine approaches, regulatory support and expedited approvals. Major trends in the forecast period include increasing incidence of end stage renal disease, advancements in treatment modalities, growing emphasis on precision medicine, development of combination therapies, technological integration in healthcare.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

Segmentation & Regional Insights

The end stage renal disease (esrd) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkalaemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

North America was the largest region in the end stage renal disease (ESRD) drug market in 2023. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

Major Driver Impacting Market Growth
Rising cases of obesity and diabetes are expected to propel the growth of the end-stage renal disease (ESRD) drug market going forward. Obesity is described as abnormal or excessive fat buildup that poses a health concern. In contrast, diabetes is a chronic condition that happens when the pancreas does not create enough insulin or when the body cannot utilize the insulin produced efficiently. In patients with renal disease, managing fluid and electrolyte levels, blood pressure, and waste product elimination through dialysis can improve general health and well-being, which may lead to weight reduction and improve blood sugar control. For instance, in March 2022, according to World Obesity, a US-based membership organization representing national and regional associations dedicated to the study and management of obesity, the number of obese people is expected to rise to 892 million in 2025 and then to 1,025 million in 2030. Furthermore, in September 2021, according to the International Diabetes Federation (IDF), a Belgium-based umbrella organization of over 230 national diabetes organizations, approximately 537 million individuals (20–79 years of age) were living with diabetes in 2021, with this figure expected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the rising cases of obesity and diabetes will drive the market for end-stage renal disease (ESRD) drugs.

Key Industry Players
Major companies operating in the end-stage renal disease (ESRD) drug market are focusing on product approvals such as Jardiance to drive revenues in their market. Empagliflozin is a drug intended to help persons with type 2 diabetes and to lower the chance of cardiovascular issues in persons with type 2 diabetes who have heart failure or cardiovascular disease. For instance, in September 2023, Boehringer Ingelheim Pharmaceuticals Inc. a US-based pharmaceutical company received FDA approval for Jardiance. Jardiance has been approved for a number of indications, such as lowering the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression, as well as lowering the risk of sustained decline in estimated glomerular filtration rate (eGFR) in adults with heart failure. Jardiance is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and is contraindicated in patients with type 1 diabetes and those with an eGFR less than 20 ml/min/1.73 m.

The end stage renal disease (esrd) drug market report table of contents includes:
1. Executive Summary
2. End Stage Renal Disease (ESRD) Drug Market Characteristics
3. End Stage Renal Disease (ESRD) Drug Market Trends And Strategies
4. End Stage Renal Disease (ESRD) Drug Market – Macro Economic Scenario
5. Global End Stage Renal Disease (ESRD) Drug Market Size and Growth
…………………………….
31. Global End Stage Renal Disease (ESRD) Drug Market Competitive Benchmarking
32. Global End Stage Renal Disease (ESRD) Drug Market Competitive Dashboard
33. Key Mergers And Acquisitions In The End Stage Renal Disease (ESRD) Drug Market
34. End Stage Renal Disease (ESRD) Drug Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model